Ryan Sullivan, MD

Articles by Ryan Sullivan, MD

Potential Impact of Tumor Infiltrating Lymphocytes on Melanoma Treatment

November 20th 2022

Ryan Sullivan, MD, explains how tumor infiltrating lymphocytes could impact the melanoma treatment landscape if approved by the FDA.

Promising Data on the Combination of Dabrafenib and Trametinib in BRAF V600-Mutant Melanoma

ByRyan Sullivan, MD

October 3rd 2019

Ryan Sullivan, MD, discusses the 5-year data pooled from the phase III COMBI-d and COMBI-v trials, which each studied dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with <em>BRAF V600</em>–mutant unresectable or metastatic melanoma.

Latest Updated Articles

Promising Data on the Combination of Dabrafenib and Trametinib in BRAF V600-Mutant Melanoma
Published: October 3rd 2019 | Updated:

Ryan Sullivan, MD

Articles by Ryan Sullivan, MD

Potential Impact of Tumor Infiltrating Lymphocytes on Melanoma Treatment

Promising Data on the Combination of Dabrafenib and Trametinib in BRAF V600-Mutant Melanoma

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors